Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy
Waqar M. Haque, Vivek Verma, Sandra S. Hatch et al. · Breast Cancer Research and Treatment · 2018
Cited by 376 works. doi:10.1007/s10549-018-4801-3
Authors
References
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes
- Residual Ductal Carcinoma In Situ in Patients With Complete Eradication of Invasive Breast Cancer After Neoadjuvant Chemotherapy Does Not Adversely Affect Patient Outcome
- DeVita, Hellman, and Rosenberg's cancer : principles & practice of oncology
- Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27
- St. Gallen 2013: Brief Preliminary Summary of the Consensus Discussion
- Handbook of Evidence-Based Radiation Oncology
- Luminal A Breast Cancer and Molecular Assays: A Review